Bezafibrate attenuates the overexpression of plasminogen activator inhibitor-1 messenger RNA by a combination of mono-unsaturated fatty acid and insulin in HepG2 cells

Life Sciences

Volumn 68, Issue 16, 2001, Pages 1827-1837

  Suzuki, Yuko ^a   Urano, Tetsumei ^a   Ihara, Hayato ^a   Nakajima, Takeshi ^b   Nagai, Nobuo ^a   Takada, Yumiko ^a   Taminato, Tomohiko ^c   Takada, Akikazu ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KAGAWA UNIVERSITY   (Japan)

Author keywords

Bezafibrate; Fatty acid; Insulin; PAI 1; Troglitazone

Indexed keywords

BEZAFIBRATE; INSULIN; MESSENGER RNA; OLEIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; TROGLITAZONE;

ARTICLE; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PROTEIN SYNTHESIS;

BEZAFIBRATE; BLOTTING, NORTHERN; CARCINOMA, HEPATOCELLULAR; CHROMANS; CULTURE MEDIA, CONDITIONED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INSULIN; LIVER NEOPLASMS; OLEIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; THIAZOLES; THIAZOLIDINEDIONES; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0035831024     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(01)00976-6     Document Type: Article

References (40)

1. On the regulation and control of fibrinolysis
2. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1
3. PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA
4. Type 1 plasminogen activator inhibitor
5. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1
6. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor
7. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis
8. PAI-1, obesity, insulin resistance and risk of cardiovascular events
9. Hypertriglyceridemia and regulation of fibrinolytic activity
10. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: Studies in randomly selected normo- and hypertriglyceridaemic men
11. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL
12. Stimulatory effect of unsaturated fatty acids on the level of plasminogen activator inhibitor-1 mRNA in cultured human endothelial cells
13. Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells
14. Linoleic acid enhances the secretion of plasminogen activator inhibitor type 1 by HepG2 cells
15. Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids
16. Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients
17. Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia
18. The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia
19. Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels
20. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia
21. Direct effects of gemfibrozil on the fibrinolytic system. Diminution of synthesis of plasminogen activator inhibitor type 1
22. Attenuation by gemfibrozil of expression of plasminogen activator inhibitor type 1 induced by insulin and its precursors
23. Plasminogen activator inhibitor type 1 secretion by HepG2 cells: Opposite effects of two fibric acid derivatives
24. Studies on the mechanism of fibrate-inhibited expression of plasminogen activator inhibitor-1 in cultured hepatocytes from cynomolgus monkey
25. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes - Role of the peroxisome proliferator-activated receptor-alpha
26. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay
27. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
28. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus
29. Induction of type-1 plasminogen activator inhibitor gene expression by thiazolidinediones during adipocyte differentiation
30. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease
31. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
32. Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: Analysis by Northern blotting and in situ hybridization
33. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity
34. Fatty acid regulation of gene expression. Transcriptional and post-transcriptional mechanisms
35. Induction of aP2 gene expression by nonmetabolized long-chain fatty acids
36. Polyunsaturated fatty acids inhibit S14 gene transcription in rat liver and cultured hepatocytes
37. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma
38. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia
39. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1
40. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity